Rationale for the use of hepatoprotective agents in the treatment of psoriasis

DOI: https://doi.org/10.29296/25877305-2018-09-20
Download full text PDF
Issue: 
9
Year: 
2018

E. Denisova(1, 2), Candidate of Medical Sciences; E. Dvoryankova(2), MD; M. Denieva(3), Candidate of Medical Sciences ; V. Sobolev(2); Professor I. Korsunskaya(1, 2), MD 1-Moscow Research-and-Practical Center for Dermatovenereology and Cosmetology 2-Center for Theoretical Problems of Physicochemical Pharmacology, Moscow 3-Republican Dermatovenereology Dispensary, Groznyi

Current studies indicate comorbidity of psoriasis and various hepatobiliary disorders. Concurrence of psoriasis and non-alcoholic fatty liver disease is most frequently encountered. The paper describes common components in the pathogenesis of these diseases, which is one of the reasons for incorporating hepatoprotective agents in the combination therapy of psoriasis. The authors’ investigation demonstrates the advantage of a drug containing essential phospholipids and glycyrrhizic acid over conventional therapy with hepatoprotective drugs.
Keywords: 
psoriasis
hepatobiliary diseases
essential phospholipids
glycyrrhizic acid

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Olisova O.Ju. Psoriaz: epidemiologija, patogenez, klinika, lechenie // Dermatologija. – 2010; 4: 3–8.
  2. Sautin M. E., Soboleva A.G., Zolotarenko A.D. i dr. Ekspressija MMP-2 i MMP-9 pri psoriaze i ateroskleroze // Ros. zhurn. kozhn. i venerich. boleznej. – 2013; 1: 27–9.
  3. Galieva N.V., Golovatenko-Abramov P.K., Nesterova A.P. i dr. Bioinformatsionnyj analiz molekuljarno-geneticheskih protsessov pri psoriaze i bolezni Krona // Sovrem. problemy dermatovenerol., immunol. i vrachebnoj kosmetol. – 2012; 3: 12–9.
  4. Kalb R., Strober B., Weinstein G. et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference // J. Am. Acaddermatol. – 2009; 60 (5): 824–37.
  5. Lindsay K., Fraser A., Layton A. et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy // Rheumatology (Oxford). – 2009; 48 (5): 569–72.
  6. Zagritdinova R.M., Filimonov M.A., Trusov V.V. i dr. Funktsional'nye narushenija gepatobiliarnoj sistemy u bol'nyh psoriazom i vozmozhnosti ih korrektsii // Vestn. dermatol. i venerol. – 2006; 3: 11–4.
  7. Jakovenko G.T., Korsunskaja I.M., Krivoschapov L.G. Ademetionin v kompleksnoj terapii psoriaza // Klin. dermatol. i venerol. – 2013; 6: 59–62.
  8. Pietrzak D., Pietrzak A., Krasowska D. et al. Digestive system in psoriasis: an update // Arch. Dermatol. Res. – 2017; 309 (9): 679–93. DOI: 10.1007/s00403-017-1775-7.
  9. Gisondi P., Targher G., Zoppini G. et al. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis // J. Hepatol. – 2009; 51: 758–64. DOI: 10.1016/j.jhep.2009.04.020.
  10. Loria P., Carulli L., Bertolotti M. et al. Endocrine and liver interaction: the role of endocrine pathways in NASH // Nat. Rev Gastroenterol. Hepatol. – 2009; 6 (4): 236–47.
  11. Mantovani A., Gisondi P., Lonardo A. et al. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? // Int. J. Mol. Sci. – 2016; 17 (2): 217.
  12. Hardwick R., Clarke J., Lake A. et al. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis // Toxicol. Sci. – 2014; 142 (1): 45–55.
  13. Denisova E.V., Dvorjankova E.V., Plieva K.T. i dr. Patologii gepatobiliarnoj sistemy u bol'nyh psoriazom // Effektivnaja farmakoterapija. Dermatologija i kosmetologija. – 2018; 1: 26–30.